Outcomes of the SARS-CoV-2 omicron (B.1.1.529) variant outbreak among vaccinated and unvaccinated patients with cancer in Europe: results from the retrospective, multicentre, OnCovid registry study
David J. Pinato(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Enrico Caliman(University of Florence), Marta Perachino(Ospedale Policlinico San Martino), Sarah Townsend(Institut Català d'Oncologia), Raffaele Giusti(CTO Andrea Alesini), Jasmine Handford(King's College London), Saira Khalique(Royal London Hospital), Rachel Sharkey(Chelsea and Westminster Hospital), Francesca Mazzoni(Azienda Ospedaliero-Universitaria Careggi), Kris Doonga(Vall d'Hebron Hospital Universitari), Elisa Roldán(Sheffield Teaching Hospitals NHS Foundation Trust), N. Saoudi Gonzalez, Lucy Rogers(Royal London Hospital), Katherine Belessiotis(Royal London Hospital), Andrea Patriarca(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Marc Cucurull(Institut Català d'Oncologia), Alberto Zambelli, Samira Bawany(Royal London Hospital), Alexia Bertuzzi(Humanitas University), Ramón Salazar(Institut Català d'Oncologia), Ailsa Sita-Lumsden(Guy's and St Thomas' NHS Foundation Trust), Ricard Mesı́a(Institut d'Investigació Biomédica de Bellvitge), Thomas Newsom-Davis(Chelsea and Westminster Hospital), María Laura Fox(Vall d'Hebron Hospital Universitari), David García-Illescas(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Gianluca Gaïdano(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Sabrina Rossi(IRCCS Humanitas Research Hospital), Isabel Ruíz-Camps(Universitat Autònoma de Barcelona), Amanda Jackson(Velindre Cancer Centre), Joan Brunet(Institut Català d'Ornitologia), Georgina Hanbury(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), M Carmen Carmona-García(Royal London Hospital), Luca Cantini, Mark Bower(Chelsea and Westminster Hospital), Andrea Plaja(Institut d'Investigació Biomédica de Bellvitge), Paolo Pedrazzoli(Policlinico San Matteo Fondazione), Federica Biello(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Oriol Mirallas(Hebron University), Daniela Ferrante(University of Washington), Bruno Vincenzi(Campus Bio Medico University Hospital), Eleanor Apthorp(King's College London), Anna Sureda(Institut d'Investigació Biomédica de Bellvitge), Alessia Dalla Pria(Hammersmith Hospital), Clara Maluquer(Institut d'Investigació Biomédica de Bellvitge), Matteo Lambertini(Ospedale Policlinico San Martino), Cian Murphy(Royal London Hospital), Riccardo Bruna(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Gianpiero Rizzo(Policlinico San Matteo Fondazione), Alasdair Sinclair(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Clara Martínez-Vila(Althaia)
Cited by 80
Related Papers
The consensus molecular subtypes of colorectal cancer
|Nature Medicine|2015|5.3k
Gastroenteropancreatic neuroendocrine tumours
|The Lancet Oncology|2008|1.8k
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
|New England Journal of Medicine|2021|1.6k
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k
Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2020|1.3k